Vascular endothelial growth factor in peritoneal dialysis: A longitudinal follow-up

Zweers, Machteld M.; Struijk, Dirk G.; Smit, Watske; Krediet, Raymond T.

doi:10.1067/mlc.2001.112235

Cited by 101 publications

(81 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the association between the fibrogenic cytokine TGF-β 1 and hypervolemia is intriguing. Zweers et al [22] have demonstrated that peritoneal effluent vascular endothelial growth factor correlated with solute transport, but TGF-β 1 did not. Our findings are in agreement with this, in that effluent TGF-β 1 did not correlate with solute transport.…”

Section: Discussionmentioning

confidence: 99%

Association between Markers of Inflammation, Fibrosis and Hypervolemia in Peritoneal Dialysis Patients

Gangji¹,

Brimble²,

Margetts³

2009

Blood Purif

View full text Add to dashboard Cite

Background/Aim: Volume expansion in peritoneal dialysis (PD) patients is associated with left ventricular hypertrophy. The link between inflammation and hypervolemia has not been extensively studied. The aim of this study was to determine if an association exists between hypervolemia and markers of inflammation in PD patients. Methods: In this cross-sectional study of 22 prevalent PD patients, volume was determined by bioelectrical impedance analysis. Serum and peritoneal effluent interleukin-6 (IL-6) and peritoneal transforming growth factor (TGF)-β₁ were measured. A fast peritoneal equilibration test determined peritoneal transport status. Results: Bioimpedance-derived measures of hypervolemia correlated with peritoneal effluent IL-6 and TGF-β₁. Peritoneal IL-6 was also associated with high peritoneal transport status. Conclusions: Markers of inflammation and fibrosis (peritoneal IL-6 and TGF-β₁) are associated with markers of hypervolemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between Markers of Inflammation, Fibrosis and Hypervolemia in Peritoneal Dialysis Patients

Gangji¹,

Brimble²,

Margetts³

2009

Blood Purif

View full text Add to dashboard Cite

show abstract

“…can produce VEGF in response to various stimuli present in the PD fl uid [33]. Level of VEGF expression in peritoneal effl uent showed a linear relationship with the duration of PD treatment [34]. This fi nding suggests that VEGF is important in the development of neo-angiogenesis and eventually in the development of EPS.…”

Section: Pathophysiology Of Epsmentioning

confidence: 69%

Encapsulating Peritoneal Sclerosis: Case report and Current Status

Issad¹

2017

Arch Clin Nephrol

View full text Add to dashboard Cite

Encapsulating peritoneal sclerosis (EPS), is a rare but devastating complication of long-term peritoneal dialysis (PD) with a high mortality rate. The incidence is between 0.5 and 3.3%, decreasing with time. EPS is defi ned as a clinical syndrome with major signs of gastrointestinal obstruction, infl ammatory parameters, radiological and macroscopic changes. Duration of treatment and cessation of PD are the main risk for development of EPS: about 75% of EPS occurred in patients transferred on hemodialysis or in the two years after kidney transplantation. Morphological alterations are disappearance of mesothelial layer, sub-mesothelial fi brosis, interstitial sclerosis and vasculopathy, ultrafi ltration failure, fast transport status of the peritoneal membrane, and loss of sodium sieving are the most predicting functional abnormalities. Some biomarkers could be found in the peritoneal effl uent. The pathophysiology is probably a consequence of a multiple-hit process in which expression of growth factors and cytokines play a role. Medical strategies (corticosteroids, immunosuppressive drugs, tamoxifen) in association with parenteral nutrition and/or surgery (enterolysis) are discussed. Prevention is the use of physiological peritoneal solutions, icodextrine instead of high glucose concentration solution, and peritoneal lavage after peritoneal dialysis cessation for any reason.

show abstract

“…The amount of locally synthesized VEGF correlated with the MTAC of creatinine and urate, glucose absorption and transcapillary ultrafiltration [17]. The local production of VEGF increased with time on PD, although the magnitude of the increase was independent of the initial VEGF levels and the duration of PD at the start of follow-up [18]. These findings indicate that individual susceptibility to as yet unknown factors may determine the extent of peritoneal VEGF production in response to dialysate exposure.…”

Section: Glucosementioning

confidence: 99%

“…These findings indicate that individual susceptibility to as yet unknown factors may determine the extent of peritoneal VEGF production in response to dialysate exposure. VEGF effluent concentrations decreased after switching to treatment with glucose-free dialysate, with a commensurate effect on the parameters of effective peritoneal surface area [18]. …”

Section: Glucosementioning

confidence: 99%

Interesting News in Peritoneal Dialysis

Vriese

2002

Nephron

View full text Add to dashboard Cite

Vascular endothelial growth factor in peritoneal dialysis: A longitudinal follow-up

Cited by 101 publications

References 17 publications

Association between Markers of Inflammation, Fibrosis and Hypervolemia in Peritoneal Dialysis Patients

Association between Markers of Inflammation, Fibrosis and Hypervolemia in Peritoneal Dialysis Patients

Encapsulating Peritoneal Sclerosis: Case report and Current Status

Interesting News in Peritoneal Dialysis

Contact Info

Product

Resources

About